Breast cancer (BC) is a highly prevalent disease, accounting for the second highest number
of cancer-related mortalities worldwide. The anthracycline doxorubicin (DOX), isolated from …

Abstract Purpose of Review Breast cancer therapies, such as anthracyclines, trastuzumab,
and chest irradiation, have well-established cardiotoxicities that lead to adverse outcomes …

Purpose Leptomeningeal carcinomatosis (MC) is commonly associated with HER2-positive
breast cancer (HER2-BC), with a poor prognosis and no standardised treatment. We …

Most HER2-positive metastatic breast cancer patients continue to relapse. Incomplete
access to all target HER2-positive cells in metastases and tumor tissues is a potential …

Breast cancer (BC) metastatic behavior varies according to the hormone receptors (HR) and
HER2 statuses. Indeed, patients with triple-negative (TN) and HER2+ tumors are at higher …

Gastric cancer (GC) is the leading cause of cancer-related mortality, and its deadly nature
can be secondary to its presentation in advanced stages. Unavailability of any gold-standard …

Adjuvant trastuzumab has been used in human epidermal growth factor-2 (HER2) breast
cancer to improve survival but with concern of cardiotoxicity. Our study is the first to review …

La terapia biológica consiste en el uso de organismos vivos, sustancias procedentes de
organismos vivos, o versiones de esas sustancias producidas en el laboratorio para el …

The introduction of Trastuzumab (Herceptin®)-based chemotherapy combinations into
standard clinical practice has revolutionized the treatment of human epidermal growth factor …

In der vorliegenden retrospektiven, deskriptiven Versorgungsanalyse wird die Therapie des
lokoregionären Rezidivs (LR)„human epidermal growth factor receptor 2 “(HER2)-positiver …